INT209881

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 9
Disease Relevance 8.92
Pain Relevance 0.86

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (TNFRSF11B, TNFSF11) cell differentiation (TNFSF11) intracellular (TNFSF11)
extracellular matrix organization (TNFRSF11B) response to stress (TNFSF11) cytoplasm (TNFSF11)
Anatomy Link Frequency
osteoclasts 6
TNFRSF11B (Homo sapiens)
TNFSF11 (Homo sapiens)
Pain Link Frequency Relevance Heat
cytokine 38 97.36 Very High Very High Very High
Osteoarthritis 87 90.64 High High
anticonvulsant 2 87.48 High High
Inflammation 76 70.80 Quite High
corticosteroid 6 70.00 Quite High
rheumatoid arthritis 116 63.00 Quite High
Arthritis 12 48.80 Quite Low
cva 28 26.40 Quite Low
agonist 6 15.04 Low Low
psoriasis 2 14.96 Low Low
Disease Link Frequency Relevance Heat
Osteoporosis 344 100.00 Very High Very High Very High
Cancer 37 100.00 Very High Very High Very High
Necrosis 23 100.00 Very High Very High Very High
Hypercalcemia 92 93.12 High High
Apoptosis 23 92.72 High High
Osteoarthritis 87 90.64 High High
Immunotherapy Of Cancer 8 86.52 High High
Lymphatic System Cancer 2 85.80 High High
Leukemia 7 85.28 High High
Disorders Of Creatine Metabolism 4 83.36 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
On the other hand, OPG is considered a decoy receptor that blocks the binding of RANKL to the RANK receptor, located on osteoclast precursors, thereby inhibiting the terminal stage of osteoclastic differentiation and suppressing its activation as well as inducing the apoptosis of mature osteoclasts.
OPG Binding (binding) of RANKL in osteoclast associated with osteoporosis and apoptosis
1) Confidence 0.36 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2246236 Disease Relevance 1.30 Pain Relevance 0.29
They are also known as osteoprotegerin (OPG) ligand and osteoclast differentiation factor based on their capacity to induce osteoclastogenesis and activate osteoclasts via RANK [19-21].
OPG Binding (ligand) of osteoclast differentiation factor in osteoclasts
2) Confidence 0.24 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906801 Disease Relevance 1.26 Pain Relevance 0.15
They are also known as osteoprotegerin (OPG) ligand and osteoclast differentiation factor based on their capacity to induce osteoclastogenesis and activate osteoclasts via RANK [19-21].
osteoprotegerin Binding (ligand) of osteoclast differentiation factor in osteoclasts
3) Confidence 0.24 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906801 Disease Relevance 1.27 Pain Relevance 0.15
B (RANK) ligand (RANKL), are known to induce the differentiation of monocytes/macrophages into osteoclasts; whereas osteoprotegerin (OPG), a soluble decoy receptor for RANKL that competes with RANK for RANKL binding, is known to suppress differentiation [1, 2].
OPG Binding (binding) of RANKL in osteoclasts
4) Confidence 0.18 Published 2009 Journal Mediators of Inflammation Section Body Doc Link PMC2829618 Disease Relevance 0.16 Pain Relevance 0.08
Denosumab mimics osteoprotegerin, which is a soluble RANKL decoy receptor that binds RANKL.
osteoprotegerin Binding (binds) of RANKL
5) Confidence 0.06 Published 2007 Journal Clinical Interventions in Aging Section Body Doc Link PMC2686344 Disease Relevance 0.45 Pain Relevance 0
B (RANK), its ligand RANKL, a member of the tumor necrosis factor (TNF) superfamily, and OPG that acts as a decoy receptor for RANKL.
OPG Binding (member) of RANKL associated with necrosis and cancer
6) Confidence 0.06 Published 2010 Journal Osteoporos Int Section Body Doc Link PMC2931762 Disease Relevance 0.89 Pain Relevance 0
B (RANK), its ligand RANKL, a member of the tumor necrosis factor (TNF) superfamily, and OPG that acts as a decoy receptor for RANKL.
OPG Binding (receptor) of RANKL associated with necrosis and cancer
7) Confidence 0.05 Published 2010 Journal Osteoporos Int Section Body Doc Link PMC2931762 Disease Relevance 0.88 Pain Relevance 0
Specifically, it enhances the osteoblastic production of osteoprotegerin, which has anti-osteoclastic properties because of its ability to bind to rankl and subsequently to block the rankl/rank interaction required for osteoclast recruitment and activation 59,60.
osteoprotegerin Binding (bind) of rankl in osteoclast associated with osteoporosis
8) Confidence 0.03 Published 2008 Journal Current Oncology Section Body Doc Link PMC2216420 Disease Relevance 1.03 Pain Relevance 0
B (RANK) and its ligand (RANKL), along with another cellular moiety - osteoprotegerin (OPG) - were found to be important participants in osteoclast differentiation and proliferation.
osteoprotegerin Binding (ligand) of RANKL in osteoclast
9) Confidence 0.01 Published 2009 Journal Pediatr Rheumatol Online J Section Body Doc Link PMC2768686 Disease Relevance 1.60 Pain Relevance 0.18

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox